PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29467959-0	2018	Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR.	apatinib	0-8	epidermal growth factor receptor	Homo sapiens	100-104	
29467959-1	2018	Objectives: This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy.	apatinib	76-84	epidermal growth factor receptor	Homo sapiens	117-121	
29467959-2	2018	Materials and Methods: We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016.	apatinib	117-125	epidermal growth factor receptor	Homo sapiens	65-69	
29467959-11	2018	Conclusions: Apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type due to its better efficacy and tolerable toxicity.	apatinib	13-21	epidermal growth factor receptor	Homo sapiens	113-117